{"protocolSection": {"identificationModule": {"nctId": "NCT00918138", "orgStudyIdInfo": {"id": "CV181-085"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg", "officialTitle": "A 4-Week, Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy of Saxagliptin in Combination With Metformin XR 1500 mg Versus Up-titrated Metformin XR to 2000 mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise and a Stable Dose of Metformin XR 1500 mg"}, "statusModule": {"statusVerifiedDate": "2015-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-08"}, "primaryCompletionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-06-09", "studyFirstSubmitQcDate": "2009-06-10", "studyFirstPostDateStruct": {"date": "2009-06-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-09-02", "resultsFirstSubmitQcDate": "2011-09-02", "resultsFirstPostDateStruct": {"date": "2011-10-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-05-04", "lastUpdatePostDateStruct": {"date": "2015-05-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study was to compare effect of Saxagliptin as add-on to Metformin on 24-hour mean weighted glucose (MWG) to the effect of uptitrating Metformin in subjects with T2DM inadequately controlled on metformin alone."}, "conditionsModule": {"conditions": ["Type 2 Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 219, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Saxagliptin + Metformin XR + matching Metformin XR placebo", "type": "EXPERIMENTAL", "description": "(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)", "interventionNames": ["Drug: Saxagliptin", "Drug: Metformin XR", "Drug: Placebo matching Metformin XR"]}, {"label": "Metformin XR + Metformin XR + matching Saxagliptin placebo", "type": "ACTIVE_COMPARATOR", "description": "(Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo)", "interventionNames": ["Drug: Metformin XR", "Drug: Placebo matching Saxagliptin"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin", "description": "Tablets, Oral, 5 mg, once daily, 4 weeks", "armGroupLabels": ["Saxagliptin + Metformin XR + matching Metformin XR placebo"], "otherNames": ["BMS-477118", "Onglyza"]}, {"type": "DRUG", "name": "Metformin XR", "description": "Tablets, Oral, 1500 mg, once daily, 4 weeks", "armGroupLabels": ["Metformin XR + Metformin XR + matching Saxagliptin placebo", "Saxagliptin + Metformin XR + matching Metformin XR placebo"], "otherNames": ["Glucophage XR\u00ae"]}, {"type": "DRUG", "name": "Placebo matching Metformin XR", "description": "Tablets, Oral, 0 mg, once daily, 4 weeks", "armGroupLabels": ["Saxagliptin + Metformin XR + matching Metformin XR placebo"]}, {"type": "DRUG", "name": "Metformin XR", "description": "Tablets, Oral, 500 mg, once daily, 4 weeks", "armGroupLabels": ["Metformin XR + Metformin XR + matching Saxagliptin placebo"], "otherNames": ["Glucophage XR\u00ae"]}, {"type": "DRUG", "name": "Placebo matching Saxagliptin", "description": "Tablets, Oral, 0 mg, once daily, 4 weeks", "armGroupLabels": ["Metformin XR + Metformin XR + matching Saxagliptin placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4", "description": "Adjusted mean change from baseline in MWG achieved with saxagliptin 5 mg plus metformin XR versus placebo plus metformin XR at Week 24. MWG was calculated as the area under the curve (AUC) for the full 24 hours expressed as average mg/dL. Glucose measurements were collected 30 minutes before and just prior to each meal (0 minutes) and 30, 60, 120, and 180 minutes after each meal (with 1 additional measurement at 240 minutes after the evening meal), midnight, 3 AM, and at end-of-domicile visit 24 hours after the first measurement. Mean change from baseline was adjusted for baseline value.", "timeFrame": "Baseline, Week 4"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Week 4 in 2-hour Postprandial Glucose (PPG) (2 Hours After the Evening Meal)", "description": "Adjusted mean change from baseline in 2-hour postprandial (after mealtime) plasma glucose two hours after start of the evening meal during 24-hour domicile visits evaluated both at pre-randomization (baseline) and at Week 4. Mean change from baseline was adjusted for baseline value.", "timeFrame": "Baseline, Week 4"}, {"measure": "Change From Baseline Fasting Plasma Glucose (FPG) at Week 4, Obtained Immediately Before the Morning Meal", "description": "FPG measurements were done at baseline, day 14 and 28. At baseline and day 28, the FPG value=plasma glucose value collected 30 minutes prior to the morning meal during the domicile visit.", "timeFrame": "Baseline, Week 4"}], "otherOutcomes": [{"measure": "Participants With Confirmed Hypoglycemia Events During the Treatment Period", "description": "'Confirmed' = recorded on the hypoglycemia AE case report form with a fingerstick for glucose \\<= 50 mg/dL and associated symptoms.", "timeFrame": "AEs: up to last treatment day (LTD) +1 day or last visit day (LVD), whichever came last ; SAEs: up to LTD +30 days or LVD + 30 days, whichever came last. Mean duration of exposure=27.7 days for Saxa 5 mg + Met XR 1500 mg, and 28.3 days for Met 2000 mg."}, {"measure": "Participants With Reported Hypoglycemic Adverse Events During Treatment Period", "description": "Hypoglycemic events are based upon the Saxagliptin Predefined List of Events, which includes hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness. The Hypoglycemic events occurred in less than 5% of the participants and hence do not appear in the adverse events module.", "timeFrame": "AEs: up to last treatment day (LTD) +1 day or last visit day (LVD), whichever came last ; SAEs: up to LTD +30 days or LVD + 30 days, whichever came last. Mean duration of exposure=27.7 days for Saxa 5 mg + Met XR 1500 mg, and 28.3 days for Met 2000 mg."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes\n* 18-78 years of age\n* Taking stable dose of metformin immediate release (IR) or XR \u2265850 mg and \u22641500 mg as monotherapy for at least 8 weeks prior to screening\n* Glycosylated hemoglobin A1C (A1C) 7.5-11.5% at screening\n* Fasting C-peptide: \u22651.0 ng/mL\n* FPG\u2265126 mg/dl obtained at the Day -7 visit\n* Body mass index (BMI): \u2264 40kg/m\u00b2\n* A1C \u2265 7.0% and \u2264 11.0% obtained at the Day -7 visit for randomization\n\nExclusion Criteria:\n\n* Women of childbearing potential unable or unwilling to use acceptable birth control\n* Women who are pregnant or breastfeeding\n* Significant cardiovascular history\n* Active liver disease\n* Renal impairment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Dedicated Phase I, Inc.", "city": "Phoenix", "state": "Arizona", "zip": "85013", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Pacific Sleep Medicine Services (Avastra Clinical Trials)", "city": "Redlands", "state": "California", "zip": "92373", "country": "United States", "geoPoint": {"lat": 34.05557, "lon": -117.18254}}, {"facility": "Orange County Research Center", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "Clinical Research Of South Florida", "city": "Coral Gables", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "Palm Springs Research Institute", "city": "Hialeah", "state": "Florida", "zip": "33012", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Healthcare Clinical Data, Inc.", "city": "North Miami", "state": "Florida", "zip": "33161", "country": "United States", "geoPoint": {"lat": 25.89009, "lon": -80.18671}}, {"facility": "River Birch Research Alliance, Llc", "city": "Blue Ridge", "state": "Georgia", "zip": "30513", "country": "United States", "geoPoint": {"lat": 34.86397, "lon": -84.32409}}, {"facility": "Jasper Clinic, Inc.", "city": "Kalamazoo", "state": "Michigan", "zip": "49007", "country": "United States", "geoPoint": {"lat": 42.29171, "lon": -85.58723}}, {"facility": "Clinilabs, Inc.", "city": "New York", "state": "New York", "zip": "10019", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Medpace Clinical Pharmacology Unit", "city": "Cincinnati", "state": "Ohio", "zip": "45212", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Clinical Trials Of Texas Inc.", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Advanced Clinical Research", "city": "West Jordan", "state": "Utah", "zip": "84088", "country": "United States", "geoPoint": {"lat": 40.60967, "lon": -111.9391}}, {"facility": "Local Institution", "city": "Capital Federal", "state": "Buenos Aires", "zip": "1429", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Buenos Aires", "zip": "1425", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Beer-Sheva", "zip": "84101", "country": "Israel", "geoPoint": {"lat": 31.25181, "lon": 34.7913}}, {"facility": "Local Institution", "city": "Holon", "zip": "58100", "country": "Israel", "geoPoint": {"lat": 32.01034, "lon": 34.77918}}, {"facility": "Local Institution", "city": "Kfar-Saba", "zip": "44281", "country": "Israel", "geoPoint": {"lat": 32.175, "lon": 34.90694}}, {"facility": "Local Institution", "city": "Zefat", "zip": "13100", "country": "Israel", "geoPoint": {"lat": 32.96465, "lon": 35.496}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Durango", "zip": "34000", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"facility": "Local Institution", "city": "Durango", "zip": "34075", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "219 participants were enrolled; 126 entered single-blind dietary/exercise/metformin extended release (XR) lead-in period (either 4- or 8-weeks long, based on pre-enrollment metformin dose). 33 participants did not enter treatment period (22 no longer met study criteria, 7 withdrew consent, 2 lost to follow-up, 1 adverse event, and 1 other reason).", "groups": [{"id": "FG000", "title": "Saxagliptin 5 mg + Metformin XR 1500 mg", "description": "saxagliptin 5 mg plus metformin XR 1500 plus matching metformin XR 500 mg placebo"}, {"id": "FG001", "title": "Metformin 2000 mg", "description": "metformin XR 500 mg plus metformin XR 1500 mg plus matching saxagliptin 5 mg placebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "46"}, {"groupId": "FG001", "numSubjects": "47"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "46"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Saxagliptin 5 mg + Metformin XR 1500 mg", "description": "saxagliptin 5 mg plus metformin XR 1500 plus matching metformin XR 500 mg placebo"}, {"id": "BG001", "title": "Metformin 2000 mg", "description": "metformin XR 500 mg plus metformin XR 1500 mg plus matching saxagliptin 5 mg placebo"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "93"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.89", "spread": "9.41"}, {"groupId": "BG001", "value": "50.64", "spread": "9.74"}, {"groupId": "BG002", "value": "52.25", "spread": "9.66"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "85"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "47"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "46"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participant", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "88"}]}]}, {"title": "Black/African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participant", "classes": [{"title": "Hispanic/Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "33"}]}]}, {"title": "Not Hispanic/ Not Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "16"}]}]}, {"title": "Not Reported", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "44"}]}]}]}, {"title": "Age categorization Females Only", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "<= 50 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "14"}]}]}, {"title": "> 50 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "32"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "91.27", "spread": "18.43"}, {"groupId": "BG001", "value": "86.94", "spread": "15.24"}, {"groupId": "BG002", "value": "89.09", "spread": "16.94"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "32.45", "spread": "5.08"}, {"groupId": "BG001", "value": "31.06", "spread": "4.28"}, {"groupId": "BG002", "value": "31.75", "spread": "4.72"}]}]}]}, {"title": "BMI Categorization", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "< 30 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "33"}]}]}, {"title": ">= 30 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "60"}]}]}]}, {"title": "Glycosylated Hemoglobin (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.6", "spread": "0.9"}, {"groupId": "BG001", "value": "8.4", "spread": "0.9"}, {"groupId": "BG002", "value": "8.5", "spread": "0.9"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "description": "The fasting value is collected at time -30 minutes prior to morning meal", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "163.5", "spread": "32.32"}, {"groupId": "BG001", "value": "164.2", "spread": "36.21"}, {"groupId": "BG002", "value": "163.8", "spread": "34.16"}]}]}]}, {"title": "FPG Categorization", "description": "The fasting value is collected at time -30 minutes prior to morning meal", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 126 mg/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}]}, {"title": ">= 126 mg/dL to < 150 mg/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "25"}]}]}, {"title": ">= 150 mg/dL to < 220 mg/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "51"}]}]}, {"title": ">= 220 mg/dL to < 300 mg/dL", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "120-minute postprandial glucose (PPG)", "description": "The 120-minute value is collected 120 minutes after start of evening meal", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "281.3", "spread": "51.59"}, {"groupId": "BG001", "value": "283.3", "spread": "66.14"}, {"groupId": "BG002", "value": "282.3", "spread": "59.08"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4", "description": "Adjusted mean change from baseline in MWG achieved with saxagliptin 5 mg plus metformin XR versus placebo plus metformin XR at Week 24. MWG was calculated as the area under the curve (AUC) for the full 24 hours expressed as average mg/dL. Glucose measurements were collected 30 minutes before and just prior to each meal (0 minutes) and 30, 60, 120, and 180 minutes after each meal (with 1 additional measurement at 240 minutes after the evening meal), midnight, 3 AM, and at end-of-domicile visit 24 hours after the first measurement. Mean change from baseline was adjusted for baseline value.", "populationDescription": "Randomized participants who had both baseline and Week 4 assessments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, Week 4", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin XR 1500 mg", "description": "saxagliptin 5 mg plus metformin XR 1500 plus matching metformin XR 500 mg placebo"}, {"id": "OG001", "title": "Metformin 2000 mg", "description": "metformin XR 500 mg plus metformin XR 1500 mg plus matching saxagliptin 5 mg placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "44"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "191.3", "spread": "6.26"}, {"groupId": "OG001", "value": "192.0", "spread": "6.14"}]}]}, {"title": "Week 4 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "173.2", "spread": "5.85"}, {"groupId": "OG001", "value": "184.2", "spread": "6.52"}]}]}, {"title": "Adjusted Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.0", "spread": "5.69"}, {"groupId": "OG001", "value": "-8.2", "spread": "5.96"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "With at least 36 participants per treatment group (72 total), there is 90% power to detect a difference of 18 mg/dL between the two treatment groups. Assuming approximately 20% of participants will discontinue without any valid post-randomization assessment at Week 4, a total of 90 participants (45 participants per treatment group) needed to be randomized.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1278", "pValueComment": "Comparison between saxagliptin 5 mg + metformin 1500 mg and metformin 2000 mg significant at alpha =0.05 according to sequential testing procedure", "statisticalMethod": "ANCOVA", "statisticalComment": "Change from baseline to week 4 was analyzed with ANCOVA including treatment group, baseline value and country in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "-10.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-24.8", "ciUpperLimit": "3.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.01", "estimateComment": "Estimate = adjusted mean change for saxagliptin 5 mg + metformin 1500 mg - adjusted mean change for metformin 2000 mg"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 4 in 2-hour Postprandial Glucose (PPG) (2 Hours After the Evening Meal)", "description": "Adjusted mean change from baseline in 2-hour postprandial (after mealtime) plasma glucose two hours after start of the evening meal during 24-hour domicile visits evaluated both at pre-randomization (baseline) and at Week 4. Mean change from baseline was adjusted for baseline value.", "populationDescription": "Randomized participants who had both baseline and Week 4 assessments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, Week 4", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin XR 1500 mg", "description": "saxagliptin 5 mg plus metformin XR 1500 plus matching metformin XR 500 mg placebo"}, {"id": "OG001", "title": "Metformin 2000 mg", "description": "metformin XR 500 mg plus metformin XR 1500 mg plus matching saxagliptin 5 mg placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "46"}]}], "classes": [{"title": "Baseline mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "229.7", "spread": "9.07"}, {"groupId": "OG001", "value": "234.0", "spread": "10.32"}]}]}, {"title": "Week 4 mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "195.3", "spread": "7.99"}, {"groupId": "OG001", "value": "228.1", "spread": "11.30"}]}]}, {"title": "Adjusted mean change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.4", "spread": "9.69"}, {"groupId": "OG001", "value": "-0.2", "spread": "10.09"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValueComment": "Comparison between saxagliptin 5 mg + metformin 1500 mg and metformin 2000 mg significant at alpha =0.05 according to sequential testing procedure.", "statisticalMethod": "ANCOVA", "statisticalComment": "Change from baseline to week 4 was analyzed with ANCOVA including treatment group, baseline value and country in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "-31.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-54.6", "ciUpperLimit": "-7.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "11.80", "estimateComment": "Estimate = adjusted mean change for saxagliptin 5 mg + metformin 1500 mg - adjusted mean change for metformin 2000 mg."}]}, {"type": "SECONDARY", "title": "Change From Baseline Fasting Plasma Glucose (FPG) at Week 4, Obtained Immediately Before the Morning Meal", "description": "FPG measurements were done at baseline, day 14 and 28. At baseline and day 28, the FPG value=plasma glucose value collected 30 minutes prior to the morning meal during the domicile visit.", "populationDescription": "Randomized participants who had both baseline and Week 4 assessments. Last Observation Carried Forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, Week 4", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin XR 1500 mg", "description": "saxagliptin 5 mg plus metformin XR 1500 plus matching metformin XR 500 mg placebo"}, {"id": "OG001", "title": "Metformin 2000 mg", "description": "metformin XR 500 mg plus metformin XR 1500 mg plus matching saxagliptin 5 mg placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"title": "Baseline mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "162.9", "spread": "4.84"}, {"groupId": "OG001", "value": "164.2", "spread": "5.28"}]}]}, {"title": "Week 4 LOCF mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "155.2", "spread": "6.49"}, {"groupId": "OG001", "value": "161.8", "spread": "5.23"}]}]}, {"title": "Adjusted mean change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.3", "spread": "5.93"}, {"groupId": "OG001", "value": "-3.6", "spread": "6.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValueComment": "Comparison between saxagliptin 5 mg + metformin 1500 mg and metformin 2000 mg significant at alpha =0.05 according to sequential testing procedure.", "statisticalMethod": "ANCOVA", "statisticalComment": "Change from baseline to week 4 was analyzed with ANCOVA including treatment group, baseline value and country in the model.", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.0", "ciUpperLimit": "8.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.18", "estimateComment": "Estimate = adjusted mean change for saxagliptin 5 mg + metformin 1500 mg - adjusted mean change for metformin 2000 mg"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Participants With Confirmed Hypoglycemia Events During the Treatment Period", "description": "'Confirmed' = recorded on the hypoglycemia AE case report form with a fingerstick for glucose \\<= 50 mg/dL and associated symptoms.", "populationDescription": "Treated participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "AEs: up to last treatment day (LTD) +1 day or last visit day (LVD), whichever came last ; SAEs: up to LTD +30 days or LVD + 30 days, whichever came last. Mean duration of exposure=27.7 days for Saxa 5 mg + Met XR 1500 mg, and 28.3 days for Met 2000 mg.", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin XR 1500 mg", "description": "saxagliptin 5 mg plus metformin XR 1500 plus matching metformin XR 500 mg placebo"}, {"id": "OG001", "title": "Metformin 2000 mg", "description": "metformin XR 500 mg plus metformin XR 1500 mg plus matching saxagliptin 5 mg placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Participants With Reported Hypoglycemic Adverse Events During Treatment Period", "description": "Hypoglycemic events are based upon the Saxagliptin Predefined List of Events, which includes hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness. The Hypoglycemic events occurred in less than 5% of the participants and hence do not appear in the adverse events module.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "AEs: up to last treatment day (LTD) +1 day or last visit day (LVD), whichever came last ; SAEs: up to LTD +30 days or LVD + 30 days, whichever came last. Mean duration of exposure=27.7 days for Saxa 5 mg + Met XR 1500 mg, and 28.3 days for Met 2000 mg.", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin XR 1500 mg", "description": "saxagliptin 5 mg plus metformin XR 1500 plus matching metformin XR 500 mg placebo"}, {"id": "OG001", "title": "Metformin 2000 mg", "description": "metformin XR 500 mg plus metformin XR 1500 mg plus matching saxagliptin 5 mg placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Metformin 2000 mg", "description": "Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo", "seriousNumAffected": 0, "seriousNumAtRisk": 47, "otherNumAffected": 0, "otherNumAtRisk": 47}, {"id": "EG001", "title": "Saxagliptin 5 mg + Metformin XR 1500 mg", "description": "Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo", "seriousNumAffected": 1, "seriousNumAtRisk": 46, "otherNumAffected": 3, "otherNumAtRisk": 46}], "seriousEvents": [{"term": "DEATH", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 47}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 46}]}], "otherEvents": [{"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 47}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 46}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M5114", "name": "Body Weight", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}